Fresenius Kabi acquires 100% stake in Dabur Pharma

Dabur Pharma has announced that the Burman family, promoters of the Dabur Group has decided to divest its entire stake in Dabur Pharma to Fresenius Kabi, a business segment of Fresenius SE, at a price of Rs 76.50 per share.

Dabur Pharma is the pharmaceutical business of the group and is focused on the attractive global ocology market. It has built up an impressive product portfolio in ocology which is being sold through its global footprint across more than 40 countries including the key markets of US and Europe. Fresenius Kabi is a business segment of the healthcare group Fresenius SE.